Status: Not yet recruiting
Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy. Participants will: Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals
Participants needed: 30
Trial details
Phase: Phase 1Age: 19+Biological sex: MaleType: InterventionalSponsor: Cellbion Co., Ltd.Updated: Nov 24, 2025
Eligibility criteria
Male patients aged 19 years or older. [+17]
Known additional malignancy that is progressing or has required active treatment... [+28]